CN116530686A - 鼠李糖乳杆菌gs014后生元组合物及其制备方法和缓解口腔溃疡的应用 - Google Patents
鼠李糖乳杆菌gs014后生元组合物及其制备方法和缓解口腔溃疡的应用 Download PDFInfo
- Publication number
- CN116530686A CN116530686A CN202310800901.8A CN202310800901A CN116530686A CN 116530686 A CN116530686 A CN 116530686A CN 202310800901 A CN202310800901 A CN 202310800901A CN 116530686 A CN116530686 A CN 116530686A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- parts
- composition
- metacomposition
- metagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 241001465754 Metazoa Species 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 208000020670 canker sore Diseases 0.000 title abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000004321 preservation Methods 0.000 claims abstract description 12
- 229920001202 Inulin Polymers 0.000 claims abstract description 11
- 229940029339 inulin Drugs 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 10
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- 239000000811 xylitol Substances 0.000 claims abstract description 10
- 229960002675 xylitol Drugs 0.000 claims abstract description 10
- 235000010447 xylitol Nutrition 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 10
- 230000012010 growth Effects 0.000 claims abstract description 8
- 241001052560 Thallis Species 0.000 claims abstract description 7
- 239000002207 metabolite Substances 0.000 claims abstract description 5
- 238000009629 microbiological culture Methods 0.000 claims abstract description 5
- 240000000103 Potentilla erecta Species 0.000 claims abstract description 4
- 235000016551 Potentilla erecta Nutrition 0.000 claims abstract description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 24
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 206010054949 Metaplasia Diseases 0.000 claims description 12
- 230000015689 metaplastic ossification Effects 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000001276 controlling effect Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 3
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 3
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 239000006872 mrs medium Substances 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000001223 reverse osmosis Methods 0.000 claims description 3
- 238000011218 seed culture Methods 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 abstract description 18
- 235000018291 probiotics Nutrition 0.000 abstract description 18
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 16
- 244000052616 bacterial pathogen Species 0.000 abstract description 14
- 230000000529 probiotic effect Effects 0.000 abstract description 12
- 241000194017 Streptococcus Species 0.000 abstract description 4
- 235000009508 confectionery Nutrition 0.000 abstract description 4
- 239000002324 mouth wash Substances 0.000 abstract description 4
- 229940051866 mouthwash Drugs 0.000 abstract description 4
- 229940034610 toothpaste Drugs 0.000 abstract description 4
- 239000000606 toothpaste Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 23
- 241000194023 Streptococcus sanguinis Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 210000000214 mouth Anatomy 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 208000007117 Oral Ulcer Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229940089837 amygdalin Drugs 0.000 description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PJVXUVWGSCCGHT-OWXXHMJUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal (3S,4S,5R)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OCC(=O)[C@@H](O)[C@@H](O)[C@H](O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO PJVXUVWGSCCGHT-OWXXHMJUSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N Arbutin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- -1 L-fucose - D-mannose - Lactose Chemical compound 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- AUTALUGDOGWPQH-VRHKARGVSA-N O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO.O=C[C@@H](O)[C@@H](O)[C@H](O)CO Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO.O=C[C@@H](O)[C@@H](O)[C@H](O)CO AUTALUGDOGWPQH-VRHKARGVSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006781 columbia blood agar Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 101150099542 tuf gene Proteins 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
- C12N1/066—Lysis of microorganisms by physical methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及鼠李糖乳杆菌GS014后生元组合物及其制备方法和缓解口腔溃疡的应用,属于益生菌的技术领域。包括重量份的以下组分:后生元30‑40份,菊粉10‑40份,木糖醇5‑15份,低聚果糖5‑10份,维生素C 0.1‑0.3份;所述后生元由鼠李糖乳杆菌GS014的菌体及代谢产物组成;所述鼠李糖乳杆菌(lactobacillus rhamnosus)GS014,其在中国微生物菌种保藏管理委员会普通微生物中心的保藏编号为CGMCC No.23646,保藏日期为2021年10月22日,保藏机构地址:北京市朝阳区北辰西路1号院3号。本发明的鼠李糖乳杆菌GS014后生元组合物能够有效的抑制口腔溃疡致病菌金黄色葡萄糖球菌和血链球菌的生长,因此可以用于制备改善口腔菌群的产品如益生菌粉、牙膏、益生菌糖果、漱口水等的日常用品。
Description
技术领域
本发明属于益生菌的技术领域,具体涉及一种鼠李糖乳杆菌GS014后生元组合物及其制备方法和缓解口腔溃疡的应用。
背景技术
口腔溃疡俗称“口疮”,是一种常见的发生于口腔黏膜的溃疡性损伤病症,常出现在口腔内唇、上颚以及舌颊等部位的黏膜上,呈圆形或精圆形的疼痛溃疡点。据统计,10%-25%的人群患有复发性口腔溃疡,好发年龄在10-30岁。口腔溃疡的发生是多种因素综合作用的结果,有害微生物(金黄色葡萄球菌和血链球菌等细菌)在口腔溃疡的发生、发展中可能起重要作用。口腔内部的菌群失调造成口腔黏膜细胞水肿变性,继而局限性坏死形成一个或多个,或大或小的溃疡面。口腔溃疡的发生可能是多种因素综合作用的结果,其包括口腔菌群失调、局部创伤、精神紧张、食物、药物、营养不良、激素水平改变及维生素或微量元素缺乏。
目前,轻型口腔溃疡一般以局部用药为主,而长期或反复发作的口腔溃疡需要同时进行局部治疗和全身治疗,长期用药会带来副作用,影响口腔内部菌群的平衡。口腔溃疡是一种多发性疾病,目前不能完全根治,所以应注重预防。
口腔微生态作为益生菌应用的新兴领域,越来越多的引发科学界和医学界的研究兴趣。后生元是益生菌经加工处理后的益生菌代谢物成分统称,包括菌体与代谢产物。日本研究证实,后生元的增强免疫能力优于原活菌,即使经由高温作用或肠胃消化液处理,仍保有高度生理活性,对人体具有多种健康助益。因此,在日常生活中如何有效利用后生元预防口腔溃疡的发生,成为现今一大热门问题。
发明内容
针对现有技术中存在的上述问题,本发明提供一种鼠李糖乳杆菌GS014后生元组合物及其制备方法和缓解口腔溃疡的应用,以解决上述问题。鼠李糖乳杆菌GS014后生元是鼠李糖乳杆菌GS014发酵液经过热处理后产生的生物活性产物,经由高温作用或肠胃消化液处理,仍保有高度生理活性,可以有效抑制致病菌的定植,改变口腔微生态的环境,从而能够预防因口腔内部菌群的失衡导致的口腔溃疡。
本发明的技术方案如下:
第一方面,本发明提供一种鼠李糖乳杆菌GS014后生元组合物,包括重量份的以下组分:后生元30-40份,菊粉10-40份,木糖醇5-15份,低聚果糖5-10份,维生素C 0.1-0.3份。所述后生元由鼠李糖乳杆菌GS014的菌体及代谢产物组成;所述鼠李糖乳杆菌(lactobacillus rhamnosus)GS014,其在中国微生物菌种保藏管理委员会普通微生物中心的保藏编号为CGMCC No. 23646,保藏日期为2021年10月22日,保藏机构地址:北京市朝阳区北辰西路1号院3号。
优选的,包括重量份的以下组分:后生元35份,菊粉25份,木糖醇10份,低聚果糖7.5份,维生素C 0.2份。
优选的,所述后生元的制备方法如下:
(1)菌种活化
无菌环境下,将保藏的鼠李糖乳杆菌GS014接种至己灭菌的MRS固体培养基上,于37℃厌氧恒温培养箱中培养72h。
(2)种子培养
从步骤(1)培养好的鼠李糖乳杆菌GS014在平板上用接种针挑取单菌落接种至已灭菌的MRS液体培养基中,于37℃静置恒温培养16h,得种子液。
(3)发酵培养
将培养好的种子液接种至已灭菌的改良MRS培养基中,37℃,50rpm,控制发酵罐的压力为0.01Mpa进行培养。培养过程中,根据发酵生长情况,适量间断性的补加60%葡萄糖溶液,自动控制流加氨水或氢氧化钠溶液控制发酵液pH值为6.5±0.5,发酵36h,得到高密度的鼠李糖乳杆菌GS014发酵液。
(4)菌体处理
将发酵液升温至70℃,维持15min,降温至30℃,然后用高压均质机进行破碎,40MPa,循环至菌体完全破碎,然后用反渗透膜进行浓缩至料液体积的三分之一,得到鼠李糖乳杆菌GS014后生元浓缩液;浓缩液经喷雾干燥得到鼠李糖乳杆菌GS014后生元。
优选的,所述步骤(3)中改良MRS培养基包括重量份的以下组分:葡萄糖10份,酵母蛋白胨10份,酵母浸粉5份,牛肉浸粉10份,磷酸二氢钾1.5份,七水硫酸镁1.5份,柠檬酸氢二铵1.5份,硫酸亚铁0.0015份,硫酸锌0.001份,硫酸锰0.001份,烟酰胺0.002份,VB70.002份,VB1 0.001份。
第二方面,本发明提供了一种含鼠李糖乳杆菌GS014后生元组合物的制备方法,具体如下:
(1)混合辅料
将菊粉、木糖醇、低聚果糖和维生素C投入水中,搅拌充分;然后加入鼠李糖乳杆菌GS014后生元,搅拌均匀。
(2)干燥
料液通过巴氏杀菌,调控进风温度,控制粉末的水分;调节雾化器的频率,控制粉末的粒度,经喷雾干燥得到鼠李糖乳杆菌GS014后生元组合物。
优选的,所述鼠李糖乳杆菌GS014后生元组合物水分<5%。
优选的,所述鼠李糖乳杆菌GS014后生元组合物粒度(D90)<100目。
第三方面,本发明还提供了鼠李糖乳杆菌GS014后生元组合物在缓解和预防口腔溃疡的应用,即可以用于制备改善口腔菌群的产品。
所述的改善口腔菌群的产品为益生菌粉、牙膏、益生菌糖果、漱口水等日常用品。
本发明的有益效果为:
本发明提供了一种鼠李糖乳杆菌GS014后生元组合物,其能够有效的抑制口腔溃疡致病菌金黄色葡萄糖球菌和血链球菌的生长,因此可以用于制备改善口腔菌群的产品如益生菌粉、牙膏、益生菌糖果、漱口水等的日常用品。为预防口腔溃疡的发生提供了一种新的防治思路。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,对于本领域普通技术人员而言,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是本发明实施例1中鼠李糖乳杆菌GS014的平板培养基生长情况图。
图2是本发明实施例2中鼠李糖乳杆菌GS014的革兰氏染色图。
图3是本发明实施例1中鼠李糖乳杆菌GS014的生长曲线图。
图4是本发明实施例6中鼠李糖乳杆菌GS014后生元组合物对人口腔上皮细胞HOEC细胞的黏附实验结果图。
图5是本发明实施例7中鼠李糖乳杆菌GS014后生元组合物对金黄葡萄球菌的抑菌图。
图6是本发明实施例7中鼠李糖乳杆菌GS014后生元组合物对血链球菌的抑菌图。
图中,1-实施例3制备的鼠李糖乳杆菌GS014后生元组合物对金黄葡萄球菌的抑菌圈;2-实施例4制备的鼠李糖乳杆菌GS014后生元组合物对金黄葡萄球菌的抑菌圈;3-实施例5制备的鼠李糖乳杆菌GS014后生元组合物对金黄葡萄球菌的抑菌圈;4-实施例3制备的鼠李糖乳杆菌GS014后生元组合物对血链球菌的抑菌圈;5-实施例4制备的鼠李糖乳杆菌GS014后生元组合物对血链球菌的抑菌圈;6-实施例5制备的鼠李糖乳杆菌GS014后生元组合物对血链球菌的抑菌圈。
具体实施方式
为了使本技术领域的人员更好地理解本发明中的技术方案,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。
实施例1
鼠李糖乳杆菌GS014的分离纯化
1、菌株的分离纯化
取1g内蒙古自治区锡林浩特健康牧民粪便,用无菌水梯度稀释107倍,取样品稀释液涂布于已灭菌的固体MRS培养基上,于37℃厌氧培养48h。根据菌落的形态、大小等特征挑取平板上面的单菌落,再在固体MRS培养基上进行划线,如此反复纯化,得到纯菌落。对分离并纯化的菌株进行革兰氏染色和接触酶试验,将革兰氏染色为阳性、接触酶试验为阴性的菌株初步确定为疑似益生菌,保藏备用。
2、鼠李糖乳杆菌GS014的鉴定
(1)菌落/菌体形态的观察
将挑选的疑似益生菌株接种至MRS固体培养基上,37℃静置培养24h,观察菌落的形态特征,结果如图1所示。
菌落形态:白色,边缘整齐,表面湿润,不透明。
对菌落进行革兰氏染色,在光学显微镜下观察形态,结果如图2所示。
革兰氏染色:杆状,阳性。
(2)菌株的生理和生化特性
依据《常见细菌系统鉴定手册》和《伯杰式系统细菌学手册》,对疑似益生菌菌株进行生理生化试验,其生理学特性见下表1.1和1.2。
表1.1-菌株生理学特性
培养温度 | 37℃ | 需氧性 | 厌氧 |
接触酶 | - | 氧化酶 | - |
表1.2-菌株生化特性
甘油 | - | 肌醇 | - | 菊糖 | - |
赤藓醇 | - | 甘露醇 | - | 松三糖 | - |
D-阿拉伯糖 | - | 山梨醇 | - | 棉子糖 | + |
L-阿拉伯糖 | + | α-甲基-D-甘露搪甙 | - | 淀粉 | - |
D-核糖 | + | α-甲基-D-葡萄糖甙 | - | 糖原 | - |
D-木糖 | - | N-乙酰-葡糖胺 | - | 木糖醇 | - |
L-木糖 | - | 苦杏仁甙 | + | 龙胆二糖 | + |
阿东醇 | - | 熊果甙 | - | D-松二糖 | - |
β-甲-D-木糖甙 | - | 七叶灵 | + | D-来苏糖 | - |
D-半乳糖 | - | 水杨苷 | + | D-塔格糖 | - |
D-葡萄糖 | + | 纤维二糖 | - | D-岩藻糖 | - |
D-果糖 | - | 麦芽糖 | + | L-岩藻糖 | - |
D-甘露糖 | - | 乳糖 | + | D-阿拉伯糖醇 | - |
L-山梨糖 | - | 蜜二糖 | + | L-阿拉伯糖醇 | - |
L-鼠李糖 | - | 蔗糖 | + | 葡萄糖酸盐 | - |
卫茅醇 | - | 海藻糖 | - | 2-酮基-葡萄糖酸盐 | - |
(3)菌株的分子生物学鉴定
将益生菌株交于中国工业微生物菌种保藏管理中心进行测序鉴定,16S rRNA基因序列已在专利《202211236601.3鼠李糖乳杆菌GS014及其在改善和调节肠道菌群中的应用》中记载。
根据菌株的菌落形态、形态学特性、生理生化特性、16S rRNA基因序列、tuf基因序列等实验数据综合分析,参考《伯杰式系统细菌学手册》,该菌株鉴定为鼠李糖乳酪杆菌,命名为鼠李糖乳杆菌GS014。该菌株在中国微生物菌种保藏管理委员会普通微生物中心的保藏编号为CGMCC No. 23646,保藏日期为2021年10月22日,保藏机构地址:北京市朝阳区北辰西路1号院3号。
(3)菌株的生理试验
将鼠李糖乳杆菌GS014菌种接种至无菌的MRS液体培养基中,摇匀,37℃静置恒温培养24h。培养过程中,每隔2h检测发酵液的pH值及菌浓(OD600值)。具体结果详见图3。
实施例2
鼠李糖乳杆菌GS014后生元的制备
(1)菌种活化
无菌环境下,将保藏的鼠李糖乳杆菌GS014接种至己灭菌的MRS固体培养基上,于37℃厌氧恒温培养箱中培养72h。
(2)种子培养
从(1)培养好的鼠李糖乳杆菌GS014在平板上用接种针挑取单菌落接种至已灭菌的MRS液体培养基中,于37℃静置恒温培养16h,得种子液。
(3)发酵培养
将培养好的种子液接种至已灭菌的改良MRS培养基中,37℃,50 rpm,控制发酵罐的压力为0.01Mpa进行培养。所述改良MRS培养基包括重量份的以下组分:葡萄糖10份,酵母蛋白胨10份,酵母浸粉5份,牛肉浸粉10份,磷酸二氢钾1.5份,七水硫酸镁1.5份,柠檬酸氢二铵1.5份,硫酸亚铁0.0015份,硫酸锌0.001份,硫酸锰0.001份,烟酰胺0.002份,VB70.002份,VB1 0.001份。培养过程中,根据发酵生长情况,适量间断性的补加60%葡萄糖溶液,自动控制流加氨水或氢氧化钠溶液控制发酵液pH值为6.5±0.5,发酵36h,得到高密度的鼠李糖乳杆菌GS014发酵液。
(4)菌体处理
将发酵液升温至70℃,维持15min,降温至30℃,然后用高压均质机进行破碎,40MPa,循环至菌体完全破碎,然后用反渗透膜进行浓缩至料液体积的三分之一,得到鼠李糖乳杆菌GS014后生元浓缩液;浓缩液经喷雾干燥得到鼠李糖乳杆菌GS014后生元。
实施例3
鼠李糖乳杆菌GS014后生元组合物的制备
(1)混合辅料
将菊粉25份,木糖醇10份,低聚果糖7.5份和维生素C 0.2份投入水1000份中,搅拌充分;然后加入鼠李糖乳杆菌GS014后生元35份,搅拌均匀。
(2)干燥
料液通过巴氏杀菌,调控进风温度,控制粉末的水分为4.8%;调节雾化器的频率,控制粉末的粒度为80目(D90),经喷雾干燥得到鼠李糖乳杆菌GS014后生元组合物。
实施例4
鼠李糖乳杆菌GS014后生元组合物的制备
(1)混合辅料
将菊粉10份,木糖醇5份,低聚果糖5份和维生素C 0.1份投入水1000份中,搅拌充分;然后加入鼠李糖乳杆菌GS014后生元30份,搅拌均匀。
(2)干燥
料液通过巴氏杀菌,调控进风温度,控制粉末的水分为4.5%;调节雾化器的频率,控制粉末的粒度为90目(D90),经喷雾干燥得到鼠李糖乳杆菌GS014后生元组合物。
实施例5
鼠李糖乳杆菌GS014后生元组合物的制备
(1)混合辅料
将菊粉40份,木糖醇15份,低聚果糖10份和维生素C 0.3份投入水1000份中,搅拌充分;然后加入鼠李糖乳杆菌GS014后生元40份,搅拌均匀。
(2)干燥
料液通过巴氏杀菌,调控进风温度,控制粉末的水分为4.9%;调节雾化器的频率,控制粉末的粒度为80目(D90),经喷雾干燥得到鼠李糖乳杆菌GS014后生元组合物。
实施例6
鼠李糖乳杆菌GS014后生元在人口腔上皮细胞HOEC细胞体外黏附的特性实验
致病菌的制备:
金黄色葡萄球菌按《GB 4789.10-2016 食品安全国家标准 食品微生物学检验 金黄色葡萄球菌检验》进行培养。
血链球菌按《GB 4789.11-2014食品安全国家标准 食品微生物学检验 β型溶血性链球菌检验》进行培养。
两个菌株培养完成后,菌液冷藏保存备用。
人口腔上皮细胞HOEC细胞的培养:将HOEC细胞置于湿热灭活的新生牛血清和双抗的DMEM细胞培养液中,37℃ CO2培养箱中孵育,每天换液一次,1周传代一次。连续培养15-20天后,将细胞接种于6孔细胞培养板内,待细胞长至单层后进行实验。
致病菌和鼠李糖乳杆菌GS014后生元组合物混合液的制备:将实施例3制备的鼠李糖乳杆菌GS014后生元2g溶于20mL无菌PBS溶液中,充分溶解,5000rpm离心2min,用无菌PBS溶液洗菌2次,用20mL PBS溶液重悬,用0.22μm滤器除菌过滤,等量分装。分别取金黄色葡萄糖球菌和血链球菌培养液100μL至上述溶液中。
黏附实验:将6孔板内的细胞培养液吸出,用灭菌的PBS溶液漂洗2遍。每孔加入1mL的致病菌、实施例3制备的鼠李糖乳杆菌GS014后生元组合物混合液和1mL新鲜的DMEM细胞培养液,37℃ CO2培养箱内,孵育2h,然后用灭菌的PBS溶液漂洗细胞5次。漂洗后,甲醇固定,革兰氏染色,在油镜(×1000)计算20个随机视野下100个细胞上黏附的细菌数(黏附指数)。鼠李糖乳杆菌GS014后生元组合物抑制口腔溃疡致病菌在人口腔上皮细胞HOEC黏附的特性实验结果见图4。
从结果可见,口腔上皮细胞HOEC上面附着为杆菌,未见到球菌形状的形态菌株,说明鼠李糖乳杆菌GS014后生元组合物能够有效的抑制口腔溃疡致病菌在人口腔上皮细胞HOEC黏附。
实施例7
鼠李糖乳杆菌GS014后生元组合物对口腔有害菌的抑菌实验
以诱发口腔溃疡的主要有害微生物金黄色葡萄糖球菌、血链球菌为指示菌,检测鼠李糖乳杆菌GS014后生元对致病菌产生的抑菌圈大小,从而判断其抑菌能力。
采用牛津杯法测定鼠李糖乳杆菌GS014后生元对致病菌的抑制作用。
致病菌的制备:金黄色葡萄球菌按《GB 4789.10-2016 食品安全国家标准 食品微生物学检验 金黄色葡萄球菌检验》进行培养,备用。
血链球菌按《GB 4789.11-2014食品安全国家标准 食品微生物学检验 β型溶血性链球菌检验》进行培养,备用。
牛津杯平皿的制备:取1ml金黄色葡萄球菌培养液与已灭菌的40℃-50℃的30mlLB固体培养基混合均匀倒入含有牛津杯的平皿中,待凝固备用;取1ml血链球菌于已灭菌的40-50℃哥伦比亚血琼脂培养基混合均匀含有牛津杯的平皿中,待凝固备用。
鼠李糖乳杆菌GS014后生元组合物混悬液的制备:在无菌环境下,将1g鼠李糖乳杆菌GS014后生元组合物置于10mL水中,充分溶解混匀,做成不同浓度的混悬液。
抑菌试验:在每个牛津杯中滴加200μL的混悬液,37℃静置恒温条件下培养72h,测量抑菌圈的直径。以未接混悬液的平皿作为空白对照。具体结果详见表2。
表2-鼠李糖乳杆菌GS014后生元组合物对口腔溃疡致病菌的的抑菌能力
金黄色葡萄球菌(mm) | 血链球菌(mm) | |
实施例3 | 16.38±0.23 | 13.92±0.17 |
实施例4 | 17.02±0.58 | 14.47±0.32 |
实施例5 | 16.45±0.37 | 13.64±0.29 |
空白 | 0 | 0 |
由表2结果可见,本发明的鼠李糖乳杆菌GS014后生元组合物能够有效的抑制口腔溃疡致病菌金黄色葡萄糖球菌和血链球菌的生长,因此可以用于制备改善口腔菌群的产品如益生菌粉、牙膏、益生菌糖果、漱口水等的日常用品。
尽管通过参考附图并结合优选实施例的方式对本发明进行了详细描述,但本发明并不限于此。在不脱离本发明的精神和实质的前提下,本领域普通技术人员可以对本发明的实施例进行各种等效的修改或替换,而这些修改或替换都应在本发明的涵盖范围内/任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以权利要求所述的保护范围为准。
Claims (8)
1.一种鼠李糖乳杆菌GS014后生元组合物,其特征在于,包括重量份的以下组分:后生元30-40份,菊粉10-40份,木糖醇5-15份,低聚果糖5-10份,维生素C 0.1-0.3份;所述后生元由鼠李糖乳杆菌GS014的菌体及代谢产物组成;所述鼠李糖乳杆菌(lactobacillusrhamnosus)GS014,其在中国微生物菌种保藏管理委员会普通微生物中心的保藏编号为CGMCC No. 23646,保藏日期为2021年10月22日,保藏机构地址:北京市朝阳区北辰西路1号院3号。
2.如权利要求1所述的鼠李糖乳杆菌GS014后生元组合物,其特征在于,包括重量份的以下组分:后生元35份,菊粉25份,木糖醇10份,低聚果糖7.5份,维生素C 0.2份。
3.如权利要求1所述的鼠李糖乳杆菌GS014后生元组合物,其特征在于,所述后生元的制备方法如下:
(1)菌种活化
无菌环境下,将保藏的鼠李糖乳杆菌GS014接种至己灭菌的MRS固体培养基上,于37℃厌氧恒温培养箱中培养72h;
(2)种子培养
从步骤(1)培养好的鼠李糖乳杆菌GS014在平板上用接种针挑取单菌落接种至已灭菌的MRS液体培养基中,于37℃静置恒温培养16h,得种子液;
(3)发酵培养
将培养好的种子液接种至已灭菌的改良MRS培养基中,37℃,50rpm,控制发酵罐的压力为0.01Mpa进行培养;培养过程中,根据发酵生长情况,适量间断性的补加60%葡萄糖溶液,自动控制流加氨水或氢氧化钠溶液控制发酵液pH值为6.5±0.5,发酵36h,得到高密度的鼠李糖乳杆菌GS014发酵液;
(4)菌体处理
将发酵液升温至70℃,维持15min,降温至30℃,然后用高压均质机进行破碎,40MPa,循环至菌体完全破碎,然后用反渗透膜进行浓缩至料液体积的三分之一,得到鼠李糖乳杆菌GS014后生元浓缩液;浓缩液经喷雾干燥得到鼠李糖乳杆菌GS014后生元。
4.如权利要求3所述的鼠李糖乳杆菌GS014后生元组合物,其特征在于,所述步骤(3)中,改良MRS培养基包括重量份的以下组分:葡萄糖10份,酵母蛋白胨10份,酵母浸粉5份,牛肉浸粉10份,磷酸二氢钾1.5份,七水硫酸镁1.5份,柠檬酸氢二铵1.5份,硫酸亚铁0.0015份,硫酸锌0.001份,硫酸锰0.001份,烟酰胺0.002份,VB7 0.002份,VB1 0.001份。
5.一种制备如权利要求1所述的鼠李糖乳杆菌GS014后生元组合物的方法,其特征在于,具体步骤如下:
(1)混合辅料
将菊粉、木糖醇、低聚果糖和维生素C投入水中,搅拌充分;然后加入鼠李糖乳杆菌GS014后生元,搅拌均匀;
(2)干燥
料液通过巴氏杀菌,调控进风温度,控制粉末的水分;调节雾化器的频率,控制粉末的粒度,经喷雾干燥得到鼠李糖乳杆菌GS014后生元组合物。
6.如权利要求5所述的方法,其特征在于,所述鼠李糖乳杆菌GS014后生元组合物水分<5%。
7.如权利要求5所述的方法,其特征在于,所述鼠李糖乳杆菌GS014后生元组合物粒度<100目。
8.一种如权利要求1所述的鼠李糖乳杆菌GS014后生元组合物在制备缓解和预防口腔溃疡产品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310800901.8A CN116530686A (zh) | 2023-07-03 | 2023-07-03 | 鼠李糖乳杆菌gs014后生元组合物及其制备方法和缓解口腔溃疡的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310800901.8A CN116530686A (zh) | 2023-07-03 | 2023-07-03 | 鼠李糖乳杆菌gs014后生元组合物及其制备方法和缓解口腔溃疡的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116530686A true CN116530686A (zh) | 2023-08-04 |
Family
ID=87458105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310800901.8A Pending CN116530686A (zh) | 2023-07-03 | 2023-07-03 | 鼠李糖乳杆菌gs014后生元组合物及其制备方法和缓解口腔溃疡的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116530686A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111363704A (zh) * | 2019-12-12 | 2020-07-03 | 石家庄君乐宝乳业有限公司 | 有益口腔健康的鼠李糖乳杆菌x253、其分离纯化方法及应用 |
CN114712298A (zh) * | 2022-03-28 | 2022-07-08 | 桂龙药业(安徽)有限公司 | 一种促进口腔健康的益生元和后生元组合物及其应用 |
CN115317522A (zh) * | 2022-07-22 | 2022-11-11 | 内蒙古科拓生物有限公司 | 一株鼠李糖乳杆菌r7970在制备病原菌抑制产品中的应用 |
CN116004436A (zh) * | 2022-10-10 | 2023-04-25 | 天津小薇生物科技有限公司 | 鼠李糖乳杆菌gs014及其在改善和调节肠道菌群中的应用 |
-
2023
- 2023-07-03 CN CN202310800901.8A patent/CN116530686A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111363704A (zh) * | 2019-12-12 | 2020-07-03 | 石家庄君乐宝乳业有限公司 | 有益口腔健康的鼠李糖乳杆菌x253、其分离纯化方法及应用 |
WO2021114659A1 (zh) * | 2019-12-12 | 2021-06-17 | 石家庄君乐宝乳业有限公司 | 有益口腔健康的鼠李糖乳杆菌x253、其分离纯化方法及应用 |
CN114712298A (zh) * | 2022-03-28 | 2022-07-08 | 桂龙药业(安徽)有限公司 | 一种促进口腔健康的益生元和后生元组合物及其应用 |
CN115317522A (zh) * | 2022-07-22 | 2022-11-11 | 内蒙古科拓生物有限公司 | 一株鼠李糖乳杆菌r7970在制备病原菌抑制产品中的应用 |
CN116004436A (zh) * | 2022-10-10 | 2023-04-25 | 天津小薇生物科技有限公司 | 鼠李糖乳杆菌gs014及其在改善和调节肠道菌群中的应用 |
Non-Patent Citations (1)
Title |
---|
姚纪高: "《肠道养好菌,身体更健康》", 中国轻工业出版社, pages: 122 - 123 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021114659A1 (zh) | 有益口腔健康的鼠李糖乳杆菌x253、其分离纯化方法及应用 | |
CN1888051B (zh) | 一株植物乳杆菌及其应用 | |
US5296221A (en) | Lactobacillus johnsonii ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations | |
CN109161498B (zh) | 枯草芽孢杆菌m406及其在制备细菌素和纤维素酶中的应用 | |
CN116004436A (zh) | 鼠李糖乳杆菌gs014及其在改善和调节肠道菌群中的应用 | |
CN111635875A (zh) | 一种长双歧杆菌cz70及其制备活菌型黑莓果浆的方法 | |
CN111849836A (zh) | 一种具有抗氧化、延长寿命的鼠李糖乳杆菌及其应用 | |
Oberhofer et al. | Isolation and cultivation of Haemophilus ducreyi | |
KR19990079232A (ko) | 콜레스테롤 저하능을 가지는 락토바실러스 플란타룸 피엠오08(케이에프씨씨-11028)미생물 | |
KR101854705B1 (ko) | 알파글루코시다아제 저해제를 다량 생산하는 바실러스 리케니포르미스 ny1505 균주 | |
CN116763829A (zh) | 植物乳杆菌lz010后生元组合物及其制备方法和抑制幽门螺杆菌的应用 | |
CN115725469B (zh) | 一株副干酪乳杆菌及其应用 | |
CN116530686A (zh) | 鼠李糖乳杆菌gs014后生元组合物及其制备方法和缓解口腔溃疡的应用 | |
KR20190075039A (ko) | 락토바실러스 플란타룸 kcc-24 및 이를 포함하는 조성물 | |
CN116004455A (zh) | 一株具有分泌5-羟色胺功能的发酵乳杆菌菌株a21196及其应用 | |
CN113956993B (zh) | 一株具有缓解人角质形成细胞氧化损伤作用的副干酪乳杆菌 | |
CN113215067B (zh) | Vbnc状态短乳杆菌cshrr5-3菌株及其应用 | |
KR19990035280A (ko) | 락토바실러스 애시도필러스 ky 2104 및 그 용도 | |
CN104673702A (zh) | 一株弯曲乳酸杆菌(Lactobacillus crispatus)及其制药用途 | |
CN114317366A (zh) | 菌株及其应用 | |
KR101696670B1 (ko) | 내산성, 내담즙성 및 세포 부착능이 우수한 락토바실러스 플랜타럼 llp5193, 및 이를 유효성분으로 포함하는 제품 | |
CN114480167A (zh) | 乳酸乳球菌md-622及其应用 | |
CN113508907A (zh) | 一株耐热型发酵乳杆菌在制备促排便食品或药品中的应用 | |
JP3052208B2 (ja) | ラクトバチルス・アシドフィルスf―133、それを用いた乳酸菌製剤及びその製造方法 | |
CN114395514B (zh) | 一株嗜酸乳杆菌、菌剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |